US · OPRX
OptimizeRx Corporation
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Waltham, MI 48307
- Website
- optimizerx.com
Price · as of 2024-12-31
$6.70
Market cap 141.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $142.27 | +2,023.43% |
| Intrinsic Value(DCF) | $2.88 | -57.01% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $3.09 | $112.21 | $0.20 | $0.00 | $0.00 |
| 2011 | $3.24 | $312.98 | $61,427.32 | $0.00 | $0.00 |
| 2012 | $3.60 | $51.57 | $42,087.35 | $0.00 | $0.00 |
| 2013 | $4.50 | $758.44 | $180,518.52 | $0.65 | $6.48 |
| 2014 | $3.90 | $277.24 | $1,354.16 | $0.00 | $0.00 |
| 2015 | $2.79 | $1,686.33 | $41.04 | $0.73 | $0.00 |
| 2016 | $2.22 | $306.13 | $0.59 | $0.01 | $0.00 |
| 2017 | $4.47 | $65.59 | $0.62 | $0.00 | $0.00 |
| 2018 | $14.80 | $246.64 | $121.04 | $1.41 | $1.59 |
| 2019 | $7.54 | $392.82 | $57.16 | $1.08 | $0.00 |
| 2020 | $45.29 | $81.97 | $404.84 | $1.63 | $0.00 |
| 2021 | $37.60 | $140.99 | $274.67 | $6.88 | $1.05 |
| 2022 | $13.09 | $96.42 | $62.40 | $2.60 | $0.00 |
| 2023 | $16.17 | $149.24 | $53.59 | $0.00 | $0.00 |
| 2024 | $4.58 | $142.27 | $2.14 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates OptimizeRx Corporation's (OPRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $142.27
- Current price
- $6.70
- AI upside
- +2,023.43%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.88
-57.01% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OPRX | OptimizeRx Corporation | $6.70 | 141.3M | +2,023% | -57% | — | — | -4.17 | 0.72 | 0.91 | -11.65 | -61.30 | 136.67 | 64.45% | -14.88% | -21.83% | -16.51% | -9.57% | -11.34% | 0.28 | -2.23 | 2.89 | 2.77 | -2.23 | 680.00% | 2881.00% | -15890.00% | 5.70% | 0.26 | 3.34% | 0.00% | 0.00% | 4.86% | -7.56 | 21.69 | 1.12 | 0.76 |
| DH | Definitive Healthcare Cor… | $1.28 | 132.23M | +1,820% | +27% | — | — | -0.61 | 0.32 | 0.50 | 0.32 | — | -1.85 | 75.88% | -8.52% | -57.52% | -48.41% | -6.39% | -21.84% | 0.02 | -1.82 | 1.64 | 1.49 | 0.96 | -6328.00% | -424.00% | -1918.00% | 30.48% | 0.34 | 12.09% | 0.00% | 0.00% | 290.32% | 2.50 | -1.39 | -0.21 | 0.60 |
| DRUG | Bright Minds Biosciences … | $83.82 | 650.57M | — | — | — | — | -63.26 | 9.43 | — | -49.84 | -36.39 | 9.43 | 0.00% | — | — | -27.93% | 3472.77% | -27.02% | 0.00 | — | 36.10 | 35.68 | 5.97 | 17385.00% | — | 36977.00% | -1.12% | -3.72 | 2165.66% | 0.00% | 0.00% | 9.98% | -49.57 | -79.48 | — | 195.16 |
| NAKA | Nakamoto Inc. | $0.25 | 92.19M | +34,449% | +169% | — | +4,954% | -2.46 | 3.46 | 3.27 | -2.47 | -1.66 | 4.08 | 96.96% | -123.05% | -133.01% | -294.13% | -619.29% | -151.45% | 0.31 | -8.51 | 4.13 | 3.81 | 0.50 | 14815.00% | -2783.00% | 64918.00% | -39.07% | -5.07 | -643.12% | 0.00% | 0.00% | 18.24% | -2.21 | -2.13 | 2.72 | 0.21 |
| NRC | National Research Corpora… | $13.41 | 303.84M | +162% | -57% | — | -83% | 26.72 | 22.16 | 2.26 | 12.73 | — | -5.94 | 56.33% | 16.44% | 8.44% | 51.24% | 16.29% | 8.68% | 5.65 | 4.74 | 0.55 | 0.42 | 2.48 | -5000.00% | -396.00% | -1790.00% | 5.08% | 0.72 | 17.46% | 3.54% | 94.60% | 10.05% | 17.04 | 24.45 | 2.80 | 2.78 |
| RXST | RxSight, Inc. | $7.48 | 307.55M | +291% | -36% | -74% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| SLP | Simulations Plus, Inc. | $12.23 | 246.39M | +509% | -44% | — | — | -5.32 | 2.76 | 4.35 | 21.26 | — | 6.64 | 58.38% | -89.33% | -81.74% | -42.13% | -51.50% | -38.12% | 0.00 | — | 7.67 | 6.98 | -2.06 | -75714.00% | 1309.00% | 3653.00% | 5.06% | 2.70 | 13.59% | 0.00% | 0.00% | 6.08% | -4.42 | 17.95 | 3.95 | 27.83 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| SOPH | SOPHiA GENETICS S.A. | $4.50 | 305.31M | +461% | -71% | — | — | -3.48 | 2.21 | 3.27 | -3.21 | — | 3.16 | 67.42% | -102.14% | -95.89% | -49.42% | -143.02% | -33.90% | 0.31 | -34.80 | 3.71 | 3.32 | 0.99 | -2213.00% | 449.00% | -1177.00% | -23.93% | -1.60 | -109.57% | 0.00% | 0.00% | 0.00% | -2.45 | -3.19 | 2.50 | -2.23 |
| SPOK | Spok Holdings, Inc. | $12.14 | 250.06M | +169% | -47% | — | -40% | 15.71 | 1.70 | 1.79 | 9.30 | 573.54 | 5.29 | 78.84% | 14.11% | 11.37% | 10.55% | 11.13% | 7.50% | 0.05 | — | 1.18 | 0.98 | -0.74 | 274.00% | 149.00% | -201.00% | 10.10% | 0.59 | 19.20% | 10.92% | 171.60% | 11.94% | 11.73 | 9.18 | 1.65 | 3.82 |
| TBRG | TruBridge, Inc. | $19.29 | 289.52M | +494% | -41% | — | — | -19.81 | 2.40 | 1.18 | 16.24 | — | -3.32 | 50.81% | 1.94% | -5.97% | -11.59% | 1.86% | -4.95% | 1.04 | 0.41 | 1.70 | 1.34 | 4.65 | -5619.00% | 95.00% | -15833.00% | 3.22% | 0.61 | 3.65% | 0.00% | 0.00% | 9.23% | 85.50 | 43.52 | 1.66 | 2.06 |
About OptimizeRx Corporation
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
- CEO
- Stephen L. Silvestro
- Employees
- 128
- Beta
- 1.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.88 ÷ $6.70) − 1 = -57.01% (DCF, example).